PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩880 per share · Prices as of the 2026-10-02 close
Huons Global posted a record annual revenue of KRW 847.5 billion in 2025, but in 2026 it faces a dual test of profitability and governance stemming from US export recall costs and a contested absorption merger involving its core biotech subsidiary Huons Lab.
2025 consolidated revenue reached a record KRW 847.5 billion with operating profit of KRW 90.6 billion, though the operating margin slipped to 10.7% from 11.9% a year earlier.
A KRW 5.3 billion product-warranty charge tied to a voluntary US injectable recall pushed subsidiary Huons into a standalone operating loss in Q1 2026, before consolidated operating profit recovered to KRW 19.5 billion in Q2.
The decision to have Huons—rather than Huons Global itself—absorb the key biotech subsidiary Huons Lab has triggered strong minority shareholder pushback, and the extraordinary general meeting remains unscheduled pending finalized dual-listing guidelines.
The company has proposed distributing 30% of the Huons shares it would receive from the merger as an in-kind dividend to general shareholders, alongside a mid-term policy to raise per-share cash dividends by 5–30% annually through 2028.
The US FDA has lifted the recall action on at least two of the three affected injectable products, raising expectations for a normalization of North American exports.
Huons Global is a pure holding company established through a spin-off in 2016, generating income through equity ownership and dividends from subsidiaries rather than operating its own business.
Its core subsidiary, Huons, focuses on prescription drugs, vitamin injectables, and basic injectable products such as local anesthetics, and has recently expanded into vaccine distribution.
Aesthetic subsidiary Humedix sells the hyaluronic acid filler brand Elravie and ophthalmic solutions, posting a record standalone quarterly revenue in the second quarter of 2026.
Huons Biopharma runs the botulinum toxin business, while Hu M&C manufactures healthcare containers such as pre-filled syringes and vials, benefiting from rising demand tied to the growing health-supplement and cosmetics markets.
In addition, biotech R&D subsidiary Huons Lab, which holds the intravenous-to-subcutaneous conversion platform Hydiffuze, has long been viewed as a key future growth driver for the group.
The company currently sits atop a diversified healthcare group comprising nine subsidiaries, four sub-subsidiaries, and one great-grandchild company.
However, a 2026 decision to have Huons Lab absorbed into operating subsidiary Huons rather than the holding company itself is fundamentally reshaping how the group's governance and the distribution of subsidiary growth benefits to holding-company shareholders will work.
Each operating company is said to run under an independent management system while cooperating organically within the group.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩212.7B | ₩25.3B | 11.9% |
| 2025Q3 | ₩211.2B | ₩20.3B | 9.6% |
| 2025Q4 | ₩224.5B | ₩19.4B | 8.6% |
| 2026Q1 | ₩197B | ₩9.2B | 4.7% |
| 2026Q2 | ₩214.1B | ₩19.5B | 9.1% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩664.4B | ₩86.5B | -₩60.3B | 13.0% | −13.0% | 58.2% |
| 2023 | ₩758.4B | ₩113.9B | ₩38.4B | 15.0% | 7.6% | 44.7% |
| 2024 | ₩813.5B | ₩97B | ₩25.8B | 11.9% | 5.0% | 45.8% |
| 2025 | ₩847.5B | ₩90.6B | ₩28.8B | 10.7% | 5.3% | 43.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-22
Consolidated revenue reached a record KRW 847.45 billion in 2025, up from KRW 813.46 billion in 2024, while operating profit fell to KRW 90.55 billion from KRW 96.99 billion, pulling the operating margin down from 11.9% to 10.7%.
Net profit attributable to owners rose to KRW 28.84 billion from KRW 25.79 billion in 2024, extending a two-year recovery trend.
After a net loss attributable to owners of KRW 60.25 billion in 2022, the company posted three consecutive years of profit at KRW 38.38 billion in 2023, KRW 25.79 billion in 2024, and KRW 28.84 billion in 2025.
On a quarterly basis, owners' net profit fell to just KRW 396 million in the second quarter of 2025 before recovering to KRW 10.78 billion in the third quarter and KRW 6.49 billion in the fourth.
However, the first quarter of 2026 saw a sharp slowdown with revenue of KRW 196.95 billion and operating profit of just KRW 9.16 billion, largely due to a KRW 5.3 billion product-warranty charge related to a voluntary US injectable recall being fully reflected in subsidiary Huons' standalone results.
In the second quarter, revenue rose to KRW 214.14 billion and operating profit recovered sharply to KRW 19.5 billion, yet owners' net profit swung to a loss of KRW 777 million, indicating that non-operating items weighed on the bottom line even as operations improved.
Summing the most recent four quarters (Q3 2025 through Q2 2026), revenue totaled roughly KRW 846.78 billion and owners' net profit around KRW 22.58 billion, illustrating a period where recovery and adjustment coexist.
The domestic pharmaceutical and healthcare industry faces two major policy variables: the government's generic drug price-cut stance and tightened regulation of dual listings and subsidiary governance structures.
The Huons Group is pursuing an inter-affiliate merger under the rationale of securing new drug pipelines and building a biopharmaceutical value chain in response to this environment, but the process has surfaced holding-company discount concerns.
In the injectable and basic pharmaceutical segment, tightening US quality-control regulation has heightened export risk for domestic manufacturers, and Huons has been affected by this trend.
In contrast, the aesthetics (filler) and health-supplement segments continue to see expanding demand both domestically and abroad, giving subsidiaries such as Humedix and Hu M&C relatively solid earnings contributions.
In the biotech innovation space, competition around subcutaneous conversion platforms for intravenous drugs is intensifying, with Alteogen widely cited as the domestic frontrunner while Huons Lab's Hydiffuze platform is viewed as a later entrant.
The diversified business portfolio under the holding structure is generally interpreted as cushioning the impact of weakness in any single segment on overall group results.
The company has stated plans to pursue earnings improvement from the second half of 2026 through strengthening its new vaccine distribution business and raising the utilization rate of the second-plant injectable line.
Expanded solid-dosage production capacity and reduced selling and administrative expenses following the absorption of subsidiary Huons Life Science are also cited as profitability drivers for the second half.
The US FDA has stated that it lifted action on at least two of the three recalled injectable products, raising the likelihood of resumed customs clearance and normalized local supply in North America.
Meanwhile, the extraordinary general meeting on the Huons–Huons Lab merger remains unscheduled pending finalization of the government's dual-listing guidelines, leaving the merger's completion timing and final structure uncertain.
The board has resolved that, should the merger proceed, 30% of the merger-related Huons shares the company would receive will be distributed as an in-kind dividend to general shareholders, excluding the largest shareholder, related parties, and treasury shares, with payment planned after the lock-up period ends and following approval at a regular shareholders' meeting.
The company has also announced a mid-term dividend policy to raise per-share cash dividends by 5–30% annually through 2028.
Huons Lab's recombinant human hyaluronidase product, Hydizyme, has had its marketing authorization application filed based on Phase 1 clinical results, and the outcome of that regulatory review remains a variable that could affect the group's biotech direction going forward.
The stock has traded within a wide band over recent years as earnings alternated between weakness and recovery, with the valuation reflecting the shift from a net loss in 2022 to consecutive profitable years from 2023 through 2025. Relative to net asset value, the shares trade at a discounted multiple to book value.
This can be interpreted as a combination of the structural discount typical of pure holding companies and market concern that, if key growth asset Huons Lab is absorbed into an operating subsidiary rather than the holding company itself, holding-company shareholders' indirect exposure to that asset would be reduced.
On the shareholder-return side, there are multiple elements at play—quarterly dividends, a mid-term policy to expand payouts, and a planned in-kind dividend contingent on the merger closing—but procedural uncertainty remains, including whether the plans will pass at the extraordinary general meeting.
Overall, the recovery in earnings direction and governance-related uncertainty together form the central axes of the current valuation discussion.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-22
The diversified business structure spanning Huons (injectables/vaccines), Humedix (fillers), and Hu M&C (containers) acts as a buffer preventing weakness in any single segment from severely shaking overall group results.
Even amid Huons' recall-related loss in Q1 2026, Humedix posted record standalone revenue and helped support group performance. This structure is seen as having contributed to the record revenue achieved in 2025.
With the US FDA lifting action on at least two of the three recalled injectable products, the likelihood of resumed North American export clearance has increased.
The company has stated that the recall stemmed from a data management system issue rather than actual product contamination, suggesting supply normalization could accelerate once system improvements are finalized. This indicates the one-off factor that weighed on Q1 2026 results is gradually being resolved.
The company has disclosed a mid-term dividend policy to raise per-share cash dividends by 5–30% annually through 2028, and its board has also resolved to distribute 30% of the Huons shares it would receive from the merger as an in-kind dividend to general shareholders should the deal close.
This is interpreted as an attempt to partly reflect general shareholders' interests amid the governance controversy.
Amid strong minority shareholder opposition to having operating subsidiary Huons—rather than the holding company—absorb Huons Lab, the extraordinary general meeting has remained unscheduled for months while awaiting finalized dual-listing guidelines from regulators.
During this period, the company's capital allocation direction and the ultimate ownership of its core biotech asset remain unclear.
Even as consolidated operating profit recovered sharply to KRW 19.5 billion in Q2 2026, net profit attributable to owners posted a loss of KRW 777 million.
This recurring gap between operating profit and owners' net profit, driven by non-operating factors or shifts in minority interest, complicates the interpretation of results.
Huons' injectable recall originated from unresolved FDA Form 483 observations, and corrective actions cascaded into global medical device kits containing the recalled products.
This shows that if US authorities continue to intensify scrutiny of domestic manufacturers' quality management systems, the possibility of similar issues recurring cannot be ruled out.
Opposition from a minority shareholder coalition over the Huons Lab absorption merger, along with disagreement over the method of limiting the largest shareholder's voting rights, remains unresolved and could weigh on investor trust regardless of the eventual vote outcome.
The controversy could also expand in connection with succession-related circumstances such as share gifts within the founding family.
The voluntary recall and customs hold on injectable exports to the US stemmed from deficiencies in a data management system, and uncertainty remains over the timing and scope of resumed customs clearance until corrective and preventive actions are fully completed. A recurrence of similar issues could further affect North American export revenue and credibility.
If the government's generic drug price-cut policy intensifies, profitability pressure could build on the pharmaceutical segment of core subsidiary Huons.
The company is responding by strengthening R&D capabilities and pursuing innovative pharmaceutical company certification, but the specific timing and scale of the policy change have not yet been finalized.
Watch for disclosure of a new date for the extraordinary general meeting on the Huons–Huons Lab merger and the finalized method for limiting the largest shareholder's voting rights.
Check whether the operating profit recovery seen in Q2 continues into Q3, and how much the normalization of US export customs clearance is reflected in revenue.
Following the shareholders' meeting vote, confirm the outcome and, if approved, how the procedure and timeline for the planned in-kind dividend (30% of merger shares) are specified.
Check the progress of the marketing authorization review for Huons Lab's recombinant human hyaluronidase product, Hydizyme.
Verify whether the mid-term dividend policy pledging annual increases of 5–30% through 2028 is actually implemented in the Q4 dividend decision.
Huons Global achieved record revenue in 2025, though its operating margin declined, and in 2026 two variables—one-off US export recall costs and a governance controversy over the ultimate ownership of core subsidiary Huons Lab—are simultaneously affecting both earnings and shareholder value assessments.
While operating profit recovered notably in Q2, net profit attributable to owners swung into a loss, and this gap between headline operating results and owners' attributable profit has appeared repeatedly.
The US FDA's lifting of recall actions is a positive signal for export normalization, but the timing of the extraordinary general meeting on the Huons Lab merger remains unset, leaving governance risk unresolved.
The company's proposed mid-term dividend expansion policy and planned in-kind dividend upon merger completion demonstrate an intent to broaden shareholder returns, though actual implementation will need to be monitored through the upcoming procedures.
The diversified business portfolio remains a structural strength that buffers the impact of weakness in any single segment. Investors should watch both the durability of the earnings recovery and the timing of resolution for the governance uncertainty.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.